IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES NOVARTIS SUBSIDIARY LISTING
Phar ma ceu ti cal Sales: US$ 9-10 mil lion
Prod ucts (% of Sales by Lead ing 5): 50-55%
Ther a peu tic Classes (% of Sales by Lead ing
5): 55-60%
Dose Forms (% of Sales by Lead ing 5):
90-95%
Prin ci pal Prod ucts:
ACC (ex pec to rant)
MOXONIDIN HEXAL (antihypertensive non-herbal
plain)
DICLAC (antirheumatic non-steroidal;
antirheumatic top i cal)
ACIC (vi ral in fec tion prod uct top i cal; an ti vi ral
non-HIV)
RAMICOR (ACE in hib i tor plain)
Ther a peu tic Range:
cough and cold prep a ra tions 17%
antihypertensives 13%
renin-an gio ten sin sys tem agents 10%
ce re bral/pe riph eral vasotherapeutics 9%
anti rheu ma tics sys temic 9%
Lead ing Dose Forms:
tab lets 46%
coated tab lets 28%
cap sules 8%
pow ders/gran ules 5%
creams 4%
LEK
Full Name: Lek Pharmaceuticals d.d., Rep re sen -
ta tive Of fice Vilnius
Street Ad dress: Seimyniskiu g. 3A, LT-09312
Vilnius
Tel: +370 52 63 60 37
Fax: +370 52 62 54 31
De scrip tion: Rep re sen ta tive of fice.
Con tacts (Pharm): Chair man: Iztok Segula;
Gen eral Con tact: Iztok Segula
NOVARTIS
Full Name: Novartis Pharma Ser vices AG, Rep re -
sen ta tive Of fice
Street Ad dress: Konstitucijos pr. 7, LT-09308
Vilnius
Tel: +370 52 69 16 50
Fax: +370 52 49 63 38
De scrip tion: Pro moter. Prod uct ranges in clude:
phar ma ceu ti cal prod ucts (branded, pre scrip tion),
hos pi tal pharmaceuticals, oph thal mic prod ucts.
Es tab lished 1996. 24 phar ma ceu ti cal employees
in 2008.
Rep re sen ta tives/De tail ers (Pharm, Num -
ber): 11-20 (2008)
Con tacts (Pharm): Com mer cial Op er a tions:
Dovydas Snaideris; Mar ket Re search: Vita
Kukiene; Gen eral Con tact: Kristina Zaveckiene
Sub sid iary of: Novartis, Swit zer land
Phar ma ceu ti cal Sales: US$ 6-7 mil lion
Prod ucts (% of Sales by Lead ing 5): 65-70%
Ther a peu tic Classes (% of Sales by Lead ing
5): 65-70%
Dose Forms (% of Sales by Lead ing 5):
95-100%
Prin ci pal Prod ucts:
TRILEPTAL (antiepileptic)
SANDIMMUN NEORAL (immunosuppressive
agent)
LEPONEX (antipsychotic)
GLIVEC (antineoplastic other)
SANDOSTATIN LAR (hor mone hy po tha lamic)
Ther a peu tic Range:
antiepileptics 28%
immunosuppressive agents 14%
psycholeptics 11%
renin-an gio ten sin sys tem agents 8%
hor mones pi tu itary and hy po tha lamic 7%
Lead ing Dose Forms:
tab lets 46%
cap sules 24%
coated tab lets 16%
vi als 7%
creams 3%
NOVARTIS CON SUMER HEALTH
Full Name: Novartis Con sumer Health Ser vices
S.A. Rep re sen ta tive Of fice Lith u a nia
Street Ad dress: Gostauto 40B, LT-01112 Vilnius
Tel: +370 52 52 65 00
Fax: +370 52 52 65 61
Phar ma ceu ti cal Sales: US$ 7-8 mil lion
Prod ucts (% of Sales by Lead ing 5): 55-60%
Ther a peu tic Classes (% of Sales by Lead ing
5): 85-90%
Dose Forms (% of Sales by Lead ing 5):
95-100%
Prin ci pal Prod ucts:
THERAFLU NON-DROWS (cold prep a ra tion with -
out anti-in fec tive)
OTRIVIN (na sal prep a ra tion top i cal)
THERAFLU NIGHT TIM (cold prep a ra tion with out
anti-in fec tive)
VIBROCIL (na sal prep a ra tion top i cal)
OTRIVIN MEN THOL (na sal prep a ra tion top i cal)
Ther a peu tic Range:
cough and cold prep a ra tions 35%
© 2009 IMS Health In cor po rated or its af fil i ates Page 186